Table 4.
Responsiveness of the EQ-5D and SF-6D to change in each of the groups, ordered by increasing magnitude of change (EQ-5D)
| Mean (s.d.) change EQ-5D | Effect size (ES) | ES ratioa | Standardised response mean (SRM) | SRM ratioa | ||||
|---|---|---|---|---|---|---|---|---|
| HΔ | EQ-5D | SF-6D | EQ-5D | SF-6D | ||||
| Deterioration | ||||||||
| BROSG | −0.05 (0.24) | ~0.20 | 0.24 | 0.15 | 1.6 | 0.22 | 0.17 | 1.3 |
| BSRBR control | −0.07 (0.28) | ~0.20 | 0.24 | 0.08 | 3.0 | 0.23 | 0.08 | 2.9 |
| BROSG(D) (1 year) | −0.13 (0.24) | ~0.20 | 0.62 | 0.35 | 1.8 | 0.51 | 0.37 | 1.4 |
| Improvement | ||||||||
| BROSG(I) (1 year) | 0.06 (0.27) | ~0.20 | 0.22 | 0.25 | 1.1 | 0.21 | 0.29 | 1.4 |
| BSRBR | 0.15 (0.34) | >0.50 | 0.46 | 0.82 | 1.8 | 0.44 | 0.64 | 1.5 |
| STIVEA | 0.20 (0.31) | ~0.50 | 0.64 | 0.97 | 1.5 | 0.64 | 0.83 | 1.3 |
HΔ hypothesised change (effect size), BROSG (D) = EQ-VAS score worse (>20% & <50%) than baseline; BROSG (I) = EQ-VAS score better (>20% & <50%) than at baseline
EQ-5D EuroQol-5D, SF-6D Short Form-6D, STIVEA steroids in very early arthritis, BROSG British Rheumatoid Outcome Study Group, BSRBR British Society for Rheumatology Biologics Register, s.d. standard deviation
aCalculated as the larger of the effect size for the EQ-5D or SF-6D divided by the smaller effect size